1.Pregnant women <br/ >2. Breastfeeding women <br/ >3. Known hypersensitivity to blood products and reactive to intradermal <br/ >sensitivity test prior to infusion <br/ >4. Receipt of pooled immunoglobulin in last 30 days <br/ >5. Critically ill patients: <br/ > a. Severe ARDS cases <br/ > b. Shock (Requiring Vasopressor to maintain a <br/ > MAP â?¥ 65mmHg or MAP below 65) <br/ >6. Participating in any other clinical trial <br/ >7. Clinical status precluding infusion of blood <br/ > products <br/ >8. Patients are not suitable for transfusion <br/ > therapy, <br/ >9. Patients with severe pneumonia defined as: RR <br/ > â?¥30 times/min or oxygen saturation â?¤ 90% in <br/ > resting state or PaO2/FiO2 â?¤ 100 mmHg or <br/ > respiratory failure and mechanical ventilation <br/ > are required or shock occurs or ICU <br/ > monitoring with presence of other organ <br/ > failure, <br/ >10. Acute life-threatening organ dysfunction <br/ > caused by a dys-regulated host response to <br/ > suspected or proven infection. (Signs of organ <br/ > dysfunction include: altered mental status, <br/ > difficult or fast breathing, low oxygen <br/ > saturation, reduced urine output, fast heart <br/ > rate, weak pulse, cold extremities <br/ > or low blood pressure, skin mottling, or <br/ > laboratory evidence of coagulopathy, <br/ > thrombocytopenia, acidosis, high lactate or <br/ > hyperbilirubinemia). <br/ >11. Patients on any other immunoglobulin or <br/ > immunomodulatory treatment, <br/ >12. Patients with known history of allergy to <br/ > horse proteins or severe allergic reactions <br/ > to any component of the Equine antiserum,

1.Pregnant women <br/ >2. Breastfeeding women <br/ >3. Known hypersensitivity to blood products and reactive to intradermal <br/ >sensitivity test prior to infusion <br/ >4. Receipt of pooled immunoglobulin in last 30 days <br/ >5. Critically ill patients: <br/ > a. Severe ARDS cases <br/ > b. Shock (Requiring Vasopressor to maintain a <br/ > MAP â?¥ 65mmHg or MAP below 65) <br/ >6. Participating in any other clinical trial <br/ >7. Clinical status precluding infusion of blood <br/ > products <br/ >8. Patients are not suitable for transfusion <br/ > therapy, <br/ >9. Patients with severe pneumonia defined as: RR <br/ > â?¥30 times/min or oxygen saturation â?¤ 90% in <br/ > resting state or PaO2/FiO2 â?¤ 100 mmHg or <br/ > respiratory failure and mechanical ventilation <br/ > are required or shock occurs or ICU <br/ > monitoring with presence of other organ <br/ > failure, <br/ >10. Acute life-threatening organ dysfunction <br/ > caused by a dys-regulated host response to <br/ > suspected or proven infection. (Signs of organ <br/ > dysfunction include: altered mental status, <br/ > difficult or fast breathing, low oxygen <br/ > saturation, reduced urine output, fast heart <br/ > rate, weak pulse, cold extremities <br/ > or low blood pressure, skin mottling, or <br/ > laboratory evidence of coagulopathy, <br/ > thrombocytopenia, acidosis, high lactate or <br/ > hyperbilirubinemia). <br/ >11. Patients on any other immunoglobulin or <br/ > immunomodulatory treatment, <br/ >12. Patients with known history of allergy to <br/ > horse proteins or severe allergic reactions <br/ > to any component of the Equine antiserum,

N/A

N/A

1.Pregnant women <br/ >2. Breastfeeding women <br/ >3. Known hypersensitivity to blood products and reactive to intradermal <br/ >sensitivity test prior to infusion <br/ >4. Receipt of pooled immunoglobulin in last 30 days <br/ >5. Critically ill patients: <br/ > a. Severe ARDS cases <br/ > b. Shock (Requiring Vasopressor to maintain a <br/ > MAP â?¥ 65mmHg or MAP below 65) <br/ >6. Participating in any other clinical trial <br/ >7. Clinical status precluding infusion of blood <br/ > products <br/ >8. Patients are not suitable for transfusion <br/ > therapy, <br/ >9. Patients with severe pneumonia defined as: RR <br/ > â?¥30 times/min or oxygen saturation â?¤ 90% in <br/ > resting state or PaO2/FiO2 â?¤ 100 mmHg or <br/ > respiratory failure and mechanical ventilation <br/ > are required or shock occurs or ICU <br/ > monitoring with presence of other organ <br/ > failure, <br/ >10. Acute life-threatening organ dysfunction <br/ > caused by a dys-regulated host response to <br/ > suspected or proven infection. (Signs of organ <br/ > dysfunction include: altered mental status, <br/ > difficult or fast breathing, low oxygen <br/ > saturation, reduced urine output, fast heart <br/ > rate, weak pulse, cold extremities <br/ > or low blood pressure, skin mottling, or <br/ > laboratory evidence of coagulopathy, <br/ > thrombocytopenia, acidosis, high lactate or <br/ > hyperbilirubinemia). <br/ >11. Patients on any other immunoglobulin or <br/ > immunomodulatory treatment, <br/ >12. Patients with known history of allergy to <br/ > horse proteins or severe allergic reactions <br/ > to any component of the Equine antiserum,

1.Pregnant women <br/ >2. Breastfeeding women <br/ >3. Known hypersensitivity to blood products and reactive to intradermal <br/ >sensitivity test prior to infusion <br/ >4. Receipt of pooled immunoglobulin in last 30 days <br/ >5. Critically ill patients: <br/ > a. Severe ARDS cases <br/ > b. Shock (Requiring Vasopressor to maintain a <br/ > MAP â?¥ 65mmHg or MAP below 65) <br/ >6. Participating in any other clinical trial <br/ >7. Clinical status precluding infusion of blood <br/ > products <br/ >8. Patients are not suitable for transfusion <br/ > therapy, <br/ >9. Patients with severe pneumonia defined as: RR <br/ > â?¥30 times/min or oxygen saturation â?¤ 90% in <br/ > resting state or PaO2/FiO2 â?¤ 100 mmHg or <br/ > respiratory failure and mechanical ventilation <br/ > are required or shock occurs or ICU <br/ > monitoring with presence of other organ <br/ > failure, <br/ >10. Acute life-threatening organ dysfunction <br/ > caused by a dys-regulated host response to <br/ > suspected or proven infection. (Signs of organ <br/ > dysfunction include: altered mental status, <br/ > difficult or fast breathing, low oxygen <br/ > saturation, reduced urine output, fast heart <br/ > rate, weak pulse, cold extremities <br/ > or low blood pressure, skin mottling, or <br/ > laboratory evidence of coagulopathy, <br/ > thrombocytopenia, acidosis, high lactate or <br/ > hyperbilirubinemia). <br/ >11. Patients on any other immunoglobulin or <br/ > immunomodulatory treatment, <br/ >12. Patients with known history of allergy to <br/ > horse proteins or severe allergic reactions <br/ > to any component of the Equine antiserum,